诱导免疫化疗后放疗治疗不可切除局部晚期非小细胞肺癌的疗效与安全性:一项回顾性研究
该回顾性研究纳入24例无法接受同步放化疗的不可切除局部晚期非小细胞肺癌患者,接受诱导免疫化疗后放疗,中位随访30.5个月,总缓解率87.5%,1年、2年、3年总生存率分别为91.7%、74.8%、57.0%,≥2级和≥3级肺炎发生率分别为37.5%和16.7%。作者认为该方案疗效令人鼓舞且毒性可接受。
要点
- 24例不可切除局部晚期非小细胞肺癌患者接受诱导免疫化疗后放疗,中位诱导4周期,中位放疗剂量60Gy。
- 总缓解率87.5%,1年、2年、3年总生存率分别为91.7%、74.8%、57.0%。
- ≥2级和≥3级肺炎发生率分别为37.5%和16.7%,任何级别放射性肺炎8例(33.3%)。
核心结论
- 作者认为,对于无法接受同步放化疗的局部晚期非小细胞肺癌患者,诱导免疫化疗后放疗及巩固免疫治疗疗效令人鼓舞且毒性可接受。
研究设计与样本
- 回顾性研究,纳入2019年1月至2022年12月在本机构接受诱导免疫化疗后放疗作为初始治疗的不可切除局部晚期非小细胞肺癌患者,共24例。
主要发现
- 患者中位年龄64岁,33.3%为ECOG体能状态评分2分,62.5%为IIIB-IIIC期。
- 自诱导免疫化疗开始的中位随访时间为30.5个月,中位诱导免疫化疗4周期,中位放疗剂量60 Gy。
- 放疗后16例(66.6%)接受巩固免疫治疗。
- 总缓解率为87.5%;1年、2年、3年总生存率分别为91.7%、74.8%、57.0%;1年、2年、3年无进展生存率分别为87.0%、54.1%、37.1%。
- ≥2级和≥3级肺炎发生率分别为37.5%和16.7%;任何级别放射性肺炎8例(33.3%),≥2级和≥3级放射性肺炎发生率分别为16.7%和12.5%。
临床怎么用
- 原文未据此给出推荐,仅报告了该回顾性研究中诱导免疫化疗后放疗及巩固免疫治疗的疗效与毒性结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immune checkpoint inhibitor (ICI) has displayed considerable advantages in consolidation therapy of locally advanced non-small cell lung cancer (LA-NSCLC) after concurrent chemoradiotherapy (cCRT). However, many patients are considered unsuitable for cCRT owing to concerns with tolerability. In this study, we aimed to assess the efficacy and toxicity of induction immunochemotherapy followed by radiotherapy for unresectable LA-NSCLC who are not capable of receiving cCRT. METHODS: From January 2019 and December 2022, LA-NSCLC patients treated with induction immunochemotherapy followed by radiotherapy as initial treatment at our institution were retrospectively reviewed. The short-term efficacy, overall survival (OS), progression free survival (PFS) and tolerability of induction immunochemotherapy followed by radiotherapy were evaluated in these patients. RESULTS: Overall, 24 patients were enrolled (median age 64 years, 33.3% with ECOG performance status score 2, and 62.5% with stage IIIB-IIIC). Median follow-up from the start of induction immunochemotherapy was 30.5 months. Median number of induction immunochemotherapy was 4 cycles. A median radiotherapy dose of 60 Gy was delivered. After radiotherapy, 16 patients (66.6%) received consolidation immunotherapy. The overall response rate in these patients was 87.5%. The 1-year, 2-year and 3-year OS were 91.7%, 74.8% and 57.0%, respectively. The 1-year, 2-year and 3-year PFS were 87.0%, 54.1% and 37.1%, respectively. The incidence of grade ≥ 2 and grade ≥ 3 pneumonitis were 37.5% and 16.7%, respectively. Radiation pneumonitis of any grade occurred in 8 patients (33.3%), and the incidence of grade ≥ 2 and grade ≥ 3 radiation pneumonitis were 16.7% and 12.5%, respectively. CONCLUSION: Induction immunochemotherapy followed by radiotherapy and consolidated immunotherapy had encouraging efficacy with acceptable toxicity for LA-NSCLC not capable of receiving cCRT.
引用
- Liu L, Gao C, Yang Y, et al. Efficacy and safety of induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced non-small cell lung cancer: A retrospective study. Radiat Oncol. 2025. PMID: 40082897. doi:10.1186/s13014-025-02616-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。